Test Price
2,800 AED✅ Home Collection Available
FGFR2 Gene (Crouzon Syndrome) Genetic Test in UAE | 2,800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189:2012 Certified Molecular Genetics Laboratory.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Genetic Counselling by a Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The FGFR2 gene analysis by Next-Generation Sequencing (NGS) is the definitive molecular test for confirming Crouzon syndrome, an autosomal dominant craniosynostosis disorder. This assay detects single nucleotide variants and small insertions/deletions across the entire coding region with exceptional analytical sensitivity. Clinical correlation with radiographic findings and family history remains essential for accurate diagnosis.
| Feature | Our Test (NGS FGFR2 Full Gene) | Closest Alternative (Limited Sanger) |
|---|---|---|
| Precision | High-sensitivity NGS covering entire FGFR2 coding region and splice sites | Targets known familial variant only; misses novel or de novo mutations |
| Method | Next-Generation Sequencing (Illumina® platform) with 50x mean depth | Sanger sequencing of one or two amplicons |
| Speed | 3–4 weeks (includes mandatory pre- and post-test genetic counselling) | 2–4 weeks (limited interpretive support) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403), states: “The FGFR2 NGS panel provides a comprehensive evaluation of the genetic basis of craniosynostosis, but results must be interpreted in the context of the full clinical presentation and three-generation pedigree. A pathogenic variant confirms the diagnosis and enables targeted surveillance for intracranial hypertension, while a negative result does not exclude all genetic etiologies. I always recommend multidisciplinary discussion with neurosurgery, ophthalmology, and clinical genetics before surgical planning.”
Medication Advisory
Important Medication Notice
Do not discontinue any prescribed therapy without first consulting your treating physician. This includes anti-epileptic drugs, corticosteroids for raised intracranial pressure, or any other chronic medication. Abrupt cessation may precipitate clinical deterioration.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active systemic infection or severe anaemia (haemoglobin <7 g/dL) – postpone sample collection until the patient is clinically stable.
- Emergency Red Flags: If the patient develops acute neurological deterioration (new-onset seizures, sudden visual loss, papilloedema, or signs of raised intracranial pressure) before sample collection, seek immediate emergency care. This is an elective genetic test and must not delay urgent neurosurgical evaluation.
Patient FAQ & Clinical Guidance
1. What does this FGFR2 genetic test detect, and who should consider it?
This test detects pathogenic variants in the FGFR2 gene that cause Crouzon syndrome, the most common syndromic craniosynostosis. It is indicated for individuals presenting with bicoronal synostosis, midface hypoplasia, ocular proptosis, and a positive family history suggestive of autosomal dominant transmission. The test aids in definitive diagnosis, differential exclusion of other craniosynostosis syndromes, and informed family planning.
2. How is the sample collected, and what is the typical turnaround time?
The preferred specimen is 3–5 mL of peripheral whole blood collected in an EDTA tube. An extracted DNA sample or a single dried blood spot on an FTA card is also acceptable. Our VIP Mobile Phlebotomy service performs ISO-certified home collection daily from 8 AM to 11 PM with full cold-chain integrity. Results are reported within 3 to 4 weeks and include a mandatory telephonic post-test genetic counselling session with a Consultant Medical Geneticist.
3. How is my genetic data protected under UAE law?
Your genetic information is classified as sensitive personal data under the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). Access is restricted to the reporting geneticist and is never shared with third parties without your explicit written consent. Testing on minors requires documented medical necessity and guardian authorisation in accordance with prevailing ethical standards. For insurance coverage verification, contact our billing team via WhatsApp.
UAE Regulatory & Data Privacy Adherence
Your privacy and safety are protected under UAE federal law.
- Data Security: All genetic and personal data are processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety: Patient consent and medical liability standards follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
- DHA Oversight: DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to all Dubai Health Authority diagnostic laboratory regulations.
Clinical & Logistical Metadata
| Test Name | FGFR2 Gene (Crouzon Syndrome) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina® Platform, 50x Mean Depth |
| ICD-10-CM Code | Q87.0 |
| LOINC Code | 93296-0 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians